This Patient Group Direction (PGD) is for the administration of COVID-19 vaccines to individuals aged 5 to 17 years, in accordance with the national COVID-19 vaccination programme.

Providers must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date.

This page is only for people who need additional support to access an NHS COVID-19 vaccine, for example, if you: need a home visit and your GP surgery has not been able to arrange this for you have severe allergies and your GP surgery has not been able to arrange this for you Most people […]

Letter from Professor Sir Stephen Powis, National Medical Director.

Classification: Official Publication reference: PRN00532 To: cc. Dear Colleagues, Access to COVID treatments I am writing to confirm that following the publication of positive NICE recommendations for COVID treatments (TA878), integrated care boards (ICBs) will have responsibility for ensuring routine access to nirmatrelvir plus ritonavir (Paxlovid) and sotrovimab (Xevudy) for eligible patients from 27 June […]

Letter from Amanda Pritchard, NHS Chief Executive and Sir David Sloman, NHS Chief Operating Officer about stepping down the COVID-19 incident level.

Letter from Professor Sir Stephen Powis setting out next steps in transitioning to routine access for COVID treatments.

Classification: Official Publication reference: PR00337 27 March 2023 To: Integrated care board (ICB) chief medical officers (CMOs) ICB COVID therapeutics senior responsible officer (SROs) Regional chief pharmacists cc: Integrated care board: Directors of commissioning Chief operating officers Lead pharmacists Dear Colleagues, Transition of COVID treatments to routine pathways Thank you for the work you and […]

These schedules to the Standard Contract are for use by commissioners to commission non-primary care providers for the COVID-19 and influenza (flu) vaccination programme from September 2023.

Letter from Sir James Mackey, National Director of Elective Recovery, NHS England and Prof Tim Briggs CBE, National Director of Clinical Improvement and Elective Recovery, NHS England.

The purpose of this commissioning framework is to support integrated care boards (ICBs) as commissioners of COVID-19 therapeutics for non-hospitalised patients who will benefit from them the most. This framework is intended to assist ICBs in establishing and maintaining timely access to COVID-19 therapeutics during the remainder of 2022/23 in preparation for routine provision from April 2023.